A viral cost estimate, a federal appeal, and what is still unknown
Evidence grade: B (unchanged). Reviewed October 2026.
Retatrutide was hard to miss this week. One widely shared post worked out what it would cost to give it to every American with obesity. Another reported that Eli Lilly is in court with the FDA over how many amino acids it contains. Both are worth a closer look, because each rests on a number that is easy to get wrong.
The viral math
The cost estimate assumed two things: a price of $1 per milligram, and 3 mg a week as a dose that works for most people.
The dose. No trial has tested 3 mg as a maintenance dose. The Phase 2 obesity trial tested 1, 4, 8 and 12 mg. The pivotal Phase 3 trial, TRIUMPH-1, tested 4, 9 and 12 mg, with 2 mg used only as a starting step. At 80 weeks, average weight loss was 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg. What 3 mg does over a year or more is not something the published evidence can tell you.
The price. Retatrutide is not approved in any country, so it has no list price. Lilly says it is legally available only to people in its clinical trials. A figure of $1 per milligram describes grey-market material that no regulator has examined. In August, Lilly announced six lawsuits against sellers of “research-use” retatrutide and said it had referred more than 200 others to authorities. A price for an unverified vial tells you nothing about what the medicine will cost.
The larger argument, that treating obesity could pay for itself, may or may not be right. It needs real doses and real prices before anyone can check it.
The court case
Under FDA rules, a “protein” is an amino acid chain with a defined sequence that is greater than 40 amino acids long. Proteins are regulated as biologics. Shorter peptides are regulated as drugs.
Retatrutide sits on that line. Its backbone has 39 amino acids. Attached to it is a side chain that Lilly says contains two more, which makes 41. The FDA says only alpha amino acids count, the side chain’s are not alpha amino acids, and the total is therefore not greater than 40.
The classification matters for two reasons:
- Exclusivity. Biologics get 12 years of protection from competition. New drugs get 5.
- Compounding. Compounding pharmacies cannot make biologics. A biologic label would close the door that let pharmacies make copies of semaglutide and tirzepatide during shortages.
Where it stands
| Date | What happened |
|---|---|
| March 18, 2024 | FDA designates retatrutide a drug, not a biologic |
| September 3, 2024 | Lilly sues in federal court in Indiana |
| September 30, 2025 | The court sides with FDA on the meaning of “protein,” and sends a second question, whether retatrutide is “analogous” to one, back to the agency |
| February 2026 | Lilly appeals to the Seventh Circuit |
| September 24, 2026 | The appeal is argued |
We found no report of a decision as of October 12.
Whichever way the court rules, it is a decision about legal category. It adds nothing to what is known about whether retatrutide works or is safe.
What is still unknown
- The pivotal trial is not yet in a journal. TRIUMPH-1 was presented in full in June. As of this review we have not found a peer-reviewed publication.
- No regulator has reviewed the safety data. Lilly has said it plans to file in early 2027. Two signals to watch are abnormal skin sensations, reported by 12.5% on the highest dose against 0.9% on placebo, and a rise in heart rate.
- There is no head-to-head result against tirzepatide. That trial is still running.
- TRIUMPH-2 was scheduled for full presentation at a European diabetes meeting on September 30. We have not yet reviewed it and will update the retatrutide page w
hen we have.
Why the grade has not changed
Nothing this week was new evidence. The trials are the same ones we graded in September. An A needs a published pivotal trial and a regulator’s review, and retatrutide has neither yet.
Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. Dose arms as summarized by Patient Care.
AJMC: Retatrutide achieves up to 30.3% average weight loss in Phase 3 TRIUMPH-1 trial. Doses, results by arm, discontinuation rates.
Reason: Can a new weight loss treatment escape the legal and regulatory thicket? September 10, 2026. The 40-amino-acid rule, each side’s count, exclusivity, Lilly’s six lawsuits.
ProfPeptide: Lilly v. Kennedy, whether retatrutide is a drug or a biologic goes to the Seventh Circuit. Case timeline and dates.
Fidj Law: Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders.
Lilly: new data at EASD 2026, including TRIUMPH-2 on September 30.
The dysesthesia figures and the trial list come from the September retatrutide page on Peptide Briefs.
Peptide Briefs is an independent reference on peptides as they appear in the scientific literature. Nothing here is medical advice or a recommendation to use any compound.
